REQUEST FOR PROPOSAL No. ABM-18042024A

In connection with the implementation by Ryvu Therapeutics S.A. of the project "The conduct of a phase II, multicentre, openlabel clinical trial (RIVER-81) evaluating the safety and efficacy of RVU120 in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia who have failed prior therapy with venetoclax and a hypomethylating agent" no. 2022/ABM/06/00002/P/02 (hereinafter: "Project") co-financed from the state budget by the Medical Research Agency under the Competition: Development of targeted or personalized medicine based on therapeutic products based on nucleic acids and small-molecule compounds no. ABM/2022/6, Ryvu Therapeutics S.A. invites proposals for the execution of the following defined description of the order.

I. ORDERING PARTY/SPONSOR

Ryvu Therapeutics S.A., Sternbacha 2, 30-394 Krakow, Poland EU VAT PL6792942955

II. DESCRIPTION OF THE ORDER

Combined services performed on the same biological samples.

Chromatin immunoprecipitation-sequencing (ChIP-seq):

QC data for the required antibodies must be available upon request.

(A) Histone Marks ChIP-Seq

no sequencing, no bioinformatic analysis, library preparation and library QC only, library ready for sequencing fulfilling common QC criteria Cells: drug-treated and control samples (duplicates) Targets: H3K27Ac, H3K27me3 (including Spike-In), H3K4me3

(B) Transcription Factors ChIP-Seq

no sequencing, no bioinformatic analysis library preparation and library QC only, library ready for sequencing fulfilling common QC criteria Cells: drug-treated and control samples (duplicates) Targets: BRD4, MED1, MED12, CDK8 **Optional target: INO80**

(C) Transcription ChIP-Seq

no sequencing, no bioinformatic analysis, library preparation and library QC only, library ready for sequencing fulfilling common QC criteria

Cells: drug-treated and control samples (duplicates) Targets: RNA Pol II, RNA Pol II phospho Ser2

(D) Input-Seq

no sequencing, no bioinformatic analysis, library preparation and library QC only, library ready for sequencing fulfilling common QC criteria library prepared from pooled 4 samples used for ChIPseq

Number of samples for service (A) to (D): <u>4 samples provided by the Ordering Party to be divided per each ChIP-seq</u> target (duplicates of treated and untreated sample), total of 37-41 libraries to be prepared as a result of this part (including Input).

(E) ATAC-Seq Service

Library and library QC only, library reaching QC requirement for sequencing Cells: drug-treated and control samples, <u>2 samples provided by the Ordering Party in duplicate</u> \rightarrow 4 samples in total, generating 4 libraries.

(F) Hi-C Service

Library and library QC only Cells: drug-treated and control (singlets), <u>2 samples provided by the Ordering Party in total, 2 libraries to be</u> <u>generated</u>.

Samples will be provided by the Ordering Party. Total number of samples: 10.

Shipment of the libraries and report (results for library preps and quality control) must be delivered to the Ordering Party by the end of May 2024. Shipping cost to be included in the total cost of the service. <u>Total number of expected libraries:</u> <u>43-47.</u>

II.2. Rules of order execution

- CONTRACT TERM: Deadline for performance of the contract: 31st May 2024.
 In the event of prolonging the completion date of the Project stage, the agreement may be extended following changes in the Project co-financing agreement.
- OFFER VALIDITY PERIOD: at least until 13th May 2024.
- **ORDER COMPLETION DATE** (TURNAROUND TIME): Required delivery of the results for library preps and quality control (QC) by the end of May 2024. Shipping cost to be included in the total cost of the service.

The turnaround time is an <u>admission condition</u>, proposal indicating a longer deadline for performance will be rejected.

III. PLACE, DATE PLACE, DATE AND PROCEDURE OF SUBMISSION OF QUOTES

- **III.1.** The proposal must be submitted by: **25**th **April 2024.**
- **III.2.** The proposal must be sent via e-mail to the following address: <u>tenders@ryvu.com</u>.
- The message with the proposal should refer to the RFP number indicated on the first page: **ABM-18042024A**. **III.3.** The proposal and its attachments must be prepared in English or Polish.
- **III.4.** The proposal should be prepared in an accordance with the form constituting Appendix 01 to this RFP.
- III.5. The Bidders must provide the price for the service for the basic service and for the optional service (Transcription Factors CHIP-Seq, target INO80) separately.

IV. ADDITIONAL INFORMATION

- **IV.1.** The Ordering Party allows for the possibility of awarding to the Contractor supplementary orders, in an amount not exceeding 50% of the value of the contract specified in the agreement concluded with the contractor, while such orders are consistent with the subject of the basic contract.
- **IV.2.** The terms and conditions of the agreement may change during the course of the agreement (Ordering Party reserves the right to amend the agreement):
 - in terms of the timelines and term of the agreement following changes in the scope of the study and Project (extension of the duration of the Project, extension of appropriate stages of the Project, change of research plans);
 - in the event of force majeure as an event which is externally impossible to foresee and which could not have been prevented and whose consequences and effects could not have been prevented.
- IV.3. The Bidders may ask the Ordering Party to clarify the content of the RFP. If the request for clarification of the content of the RFP was received later than by the end of 23rd April 2024, the Ordering Party may provide explanations or leave the application unexamined. Questions must be sent to the following e-mail address: <u>tenders@ryvu.com</u>.
- **IV.4.** The Ordering Party reserves the right to change the content of the RFP, including changes in the terms of the procedure. Bidders will be informed.
- **IV.5.** Whenever the Ordering Party uses trademarks/brands/standards/manufacturer's names in the documentation, it shall be assumed that the wording "or equivalent" is used in reference to them, thus it is acceptable to submit a tender indicating an equivalent subject matter of the contract to that described by the Ordering Party. The indications in relation to the expected technical parameters, as well as the indications in relation to specific types and manufacturers' names are of a general nature, referring only to exemplary indications of equivalent products and do not constitute the only acceptable solution. On this basis, the Ordering Party accepts equivalent solutions. A contractor who submits an equivalent offer is obliged to prove, under pain of rejection of the offer, that the submitted offer is equivalent to the one described by the Ordering Party.
- **IV.6.** The Ordering Party reserves the right to ask the Bidders at any stage of the evaluation of proposals for additional information, documents, additions or explanations. The Ordering Party's contact with the Bidder will take place by e-mail indicated in the content of the proposal sent by the Bidder.
- **IV.7.** This RFP serves to estimate the market price of the contract. The Ordering Party reserves the right to enter into negotiations with Bidders who have submitted a proposal and meets the conditions for participating in the proceedings. Arrangements regarding the date of negotiations will be carried out by e-mail. The modified proposal may not contain conditions less favorable than the original proposal.
- **IV.8.** This RFP does not oblige the Ordering Party to conclude a contract.
- **IV.9.** For more information, please contact Anna Dziedzicka at the following email address: <u>tenders@ryvu.com</u>.

ATTACHMENTS

Appendix 01 – Proposal Form

APPENDIX 01 TO RFP no. ABM-18042024A THE PROPOSAL FORM

Data of the Bidder	
Name: Address:	
Tax ID/EU VAT:	
Person authorized to contact the Ordering Party:	
name and surname:	
e-mail address:	
	Answer / confirmation of compliance *- delete inappropriate
Chromatin immunoprecipitation-sequencing (ChIP-seq): QC data for the required antibodies must be available upon requ	est.
(A) Histone Marks ChIP-Seq no sequencing, no bioinformatic analysis, library preparation QC only, library ready for sequencing fulfilling common QC c Cells: drug-treated and control samples (duplicates) Targets: H3K27Ac, H3K27me3 (including Spike-In), H3K4me3	
(B) Transcription Factors ChIP-Seq no sequencing, no bioinformatic analysis library preparation QC only, library ready for sequencing fulfilling common QC c Cells: drug-treated and control samples (duplicates) Targets: BRD4, MED1, MED12, CDK8 Optional target: INO80	
(C) Transcription ChIP-Seq no sequencing, no bioinformatic analysis, library preparation QC only, library ready for sequencing fulfilling common QC c Cells: drug-treated and control samples (duplicates) Targets: RNA Pol II, RNA Pol II phospho Ser2	
(D) Input-Seq no sequencing, no bioinformatic analysis, library preparation QC only, library ready for sequencing fulfilling common QC c library prepared from pooled 4 samples used for ChIPseq. Number of samples for service (A) to (D): <u>4 samples provided</u> <u>Ordering Party to be divided per each ChIP-seq target (duplid treated and untreated sample), total of 37-41 libraries to be as a result of this part (including Input).</u>	iteria YES/NO*
(E) ATAC-Seq Service Library and library QC only, library reaching QC requirement sequencing Cells: drug-treated and control samples, <u>2 samples provided</u> <u>Ordering Party in duplicate → 4 samples in total, generating</u>	by the
(F) Hi-C Service Library and library QC only Cells: drug-treated and control (singlets), <u>2 samples provided</u> <u>Ordering Party in total</u> , <u>2 libraries to be generated</u> .	by the
Samples will be provided by the Ordering Party. <u>Total numbe</u> <u>samples: 10.</u> Shipment of the libraries and report (results for library preps control) must be delivered by the end of May 2024. Shipping included in the total cost of the service. <u>Total number of expe</u> <u>libraries: 43-47.</u>	and quality cost to be
CONTRACT TERM : Deadline for performance of the contract: 31 ^s	May 2024. YES/NO*
ORDER COMPLETION DATE (TURNAROUND TIME): 31st May 2024	
OFFER VALIDITY PERIOD : at least until 13 th May 2024.	YES/NO*
of performing <u>service given i</u>	NET PRICE n points (A)-(F), including shipping cost without optional INO80 target

NET PRICE n Factors ChIP-Seq, target INO80	price for performing only optional target: Transcri
TOTAL NET PRICE	
ts (A)-(F) including shipping cost	of performing service given in
including optional INO80 target	

We confirm that the scope of the service offered is consistent with the subject of the request of the RFP no. ABM-18042024A.

Signature of the authorized person

Place and date